Pharmatest Services LLC is newly established US based contract research organization (CRO) operating in Massachusetts. It offers preclinical efficacy services in oncology and skeletal diseases. The company is a fully owned subsidiary of Pharmatest Services Ltd based in Finland.
In skeletal diseases, Pharmatest offers models of osteoporosis and osteoarthritis. In oncology Pharmatest has special expertise in clinically predictive orthotopic and metastasis models. The company has been a global provider of models of bone metastasis since 2007. As bone experts, Pharmatest also offers bone safety studies.
Chief executive officer (CEO) of Pharmatest Jussi Halleen comments: "Our US sales have grown more than 50% per year in the past years. We expect the growth to continue also in the coming years, and we established the LLC to be able to better serve our US customers. When the business grows it is our long-term goal to offer more jobs for skilled people in the US."
Andrew Heiniluoma is the manager of Pharmatest Services LLC and responsible for the operations. He says: "I am thrilled to see how the expertise and high-quality preclinical services of Pharmatest will help American drug development companies to save time, money and effort, and at the same time develop compounds that are more effective in the clinic."
Join Pharmatest for an educational seminar about the importance of preclinical bone metastasis studies in Boston on 6 September in an event held together with Taconic Biosciences.